Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELUTNASDAQ:GRCENASDAQ:HLVXNASDAQ:OPTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELUTElutia$2.10+13.5%$1.91$1.61▼$5.24$86.35M0.8643,951 shs43,150 shsGRCEGrace Therapeutics$2.97+1.0%$2.82$1.75▼$4.97$41.08M0.8953,117 shs21,118 shsHLVXHilleVax$1.97+1.0%$1.90$1.34▼$15.25$98.78M0.74462,801 shs4.27 million shsOPTNOptiNose$9.60$9.51$4.82▼$19.50$97.22M-0.8862,481 shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELUTElutia0.00%+16.02%+16.67%-17.00%-57.66%GRCEGrace Therapeutics0.00%-1.00%+6.45%+30.26%+296,999,900.00%HLVXHilleVax0.00%+5.91%+6.78%+35.86%-86.38%OPTNOptiNose0.00%0.00%0.00%+4.69%-38.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELUTElutia3.8709 of 5 stars3.55.00.00.03.43.30.6GRCEGrace Therapeutics2.3673 of 5 stars3.50.00.00.02.00.81.3HLVXHilleVax3.2195 of 5 stars3.03.00.00.02.73.31.3OPTNOptiNose0.6836 of 5 stars1.00.00.04.20.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELUTElutia 3.00Buy$8.00280.95% UpsideGRCEGrace Therapeutics 3.00Buy$12.00304.04% UpsideHLVXHilleVax 2.00Hold$3.0052.28% UpsideOPTNOptiNose 2.00Hold$9.00-6.25% DownsideCurrent Analyst Ratings BreakdownLatest GRCE, HLVX, OPTN, and ELUT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.005/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.003/31/2025HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELUTElutia$24.38M3.54N/AN/A($1.31) per share-1.60GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/AHLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/AOPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELUTElutia-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%7/28/2025 (Estimated)GRCEGrace Therapeutics-$9.57M-$1.16N/AN/AN/AN/A-19.45%-16.99%N/AHLVXHilleVax-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)OPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)Latest GRCE, HLVX, OPTN, and ELUT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23-$0.21+$0.02$0.01N/AN/A5/13/2025Q1 2025OPTNOptiNose-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELUTElutiaN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELUTElutiaN/A0.810.70GRCEGrace TherapeuticsN/A11.7711.77HLVXHilleVaxN/A25.3225.32OPTNOptiNoseN/A0.790.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELUTElutia74.03%GRCEGrace Therapeutics6.08%HLVXHilleVax86.42%OPTNOptiNose85.60%Insider OwnershipCompanyInsider OwnershipELUTElutia27.60%GRCEGrace Therapeutics13.51%HLVXHilleVax24.90%OPTNOptiNose2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELUTElutia18041.12 million29.77 millionNot OptionableGRCEGrace TherapeuticsN/A13.83 million11.96 millionN/AHLVXHilleVax2050.14 million37.66 millionNot OptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableGRCE, HLVX, OPTN, and ELUT HeadlinesRecent News About These CompaniesParatek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty TherapiesMay 21, 2025 | finance.yahoo.comOptinose Stockholders Approve Merger with ParatekMay 16, 2025 | tipranks.comOptiNose (OPTN) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNApril 29, 2025 | businesswire.comOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comOptinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comOptiNose (OPTN) Reports Q4 Loss, Tops Revenue EstimatesMarch 26, 2025 | zacks.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25, 2025 | morningstar.comMWall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to TradeMarch 24, 2025 | zacks.comOptinose downgraded to Neutral from Buy at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNMarch 21, 2025 | businesswire.comOPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekMarch 21, 2025 | zacks.comOptinose downgraded to Neutral from Overweight at Piper SandlerMarch 21, 2025 | markets.businessinsider.comOptinose downgraded to Hold from Buy at Lake StreetMarch 21, 2025 | markets.businessinsider.comLake Street Downgrades OptiNose (OPTN)March 21, 2025 | msn.comWhy OptiNose Inc. (OPTN) Surged On Thursday?March 21, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of ShareholdersMarch 21, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | gurufocus.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRCE, HLVX, OPTN, and ELUT Company DescriptionsElutia NASDAQ:ELUT$2.10 +0.25 (+13.51%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.04 -0.06 (-2.62%) As of 06/27/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Grace Therapeutics NASDAQ:GRCE$2.97 +0.03 (+1.02%) As of 06/27/2025 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.HilleVax NASDAQ:HLVX$1.97 +0.02 (+1.03%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.97 0.00 (0.00%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.OptiNose NASDAQ:OPTN$9.60 0.00 (0.00%) As of 05/21/2025OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
